These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 21816321)

  • 1. Prognostic significance of triglyceride-glucose index in acute coronary syndrome patients without standard modifiable cardiovascular risk factors.
    Zhang X; Du Y; Zhang T; Zhao Z; Guo Q; Ma X; Shi D; Zhou Y
    Cardiovasc Diabetol; 2024 Jul; 23(1):270. PubMed ID: 39044255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study.
    Jiao Y; Su Y; Shen J; Hou X; Li Y; Wang J; Liu B; Qiu D; Sun Z; Chen Y; Xi Q; Shen M; Fu Z
    Cardiovasc Diabetol; 2022 Jan; 21(1):3. PubMed ID: 34991602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
    Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
    J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.
    Dobiásová M
    Clin Chem; 2004 Jul; 50(7):1113-5. PubMed ID: 15229146
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
    Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance.
    Bell DS; O'Keefe JH
    J Am Coll Cardiol; 2011 Aug; 58(7):778. PubMed ID: 21816321
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
    Hanefeld M
    Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-atherosclerotic effect of pioglitazone--the first evidence of the role of triglyceride/HDL ratio].
    Császár A
    Lege Artis Med; 2011 Feb; 21(2):105-11. PubMed ID: 21710708
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.